ArticleOpen forum infectious diseases2025
Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study Data.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Improving cohort coverage estimation using a data triangulation framework: the Swiss HIV Cohort Study example.AIDS (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In Switzerland detailed individual patient data are lacking on trends in health care costs, major drivers of costs, and the contribution of breakthrough innovations, such as direct-acting agents (DAAs) for the treatment of chronic hepatitis C virus (HCV) infection in people with HIV (PWH). Methods: We linked anonymized data of patients undergoing antiretroviral therapy (ART) or naive patients initiating ART between 2012 and 2017 in the Swiss HIV Cohort Study with claims data of health insurers covering 35% of Swiss residents. Trends in mean annual costs for overall care, ART, and hospitalizations were calculated with an adjustment of costs for censoring. Changes in costs over time in relation to patient characteristics, comorbidities, and treatment of HCV with DAAs were estimated by linear mixed models. Costs were reported in Swiss francs (CHF). Results: The final linked file contained 1830 individuals from 11 286 participants of the Swiss HIV Cohort Study and 5406 claims records (33.9%). The mean adjusted annual overall cost in 2012 was CHF 24 713 (SD, 14 107) and increased in 2017 by 1.2% to CHF 24 881 (SD, 14 523). Costs for ART contributed by far most to overall costs but decreased over time. Mean costs for hospitalizations increased with annual variation by 7.2% from CHF 8727 (SD, 10 473) in 2012 to CHF 9406 (SD, 9696) in 2017. Mean increases of costs for DAAs for 171 PWH coinfected with HCV (9.4%) were CHF 52 647 (95% CI, 50 862-54 431; Conclusions: Increases in mean total costs for PWH in Switzerland from 2012 to 2017 were small. The contribution of DAAs for the treatment of chronic HCV to overall costs was marginal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.